Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Classic Induction (CI) is a standardized pharmacological regimen used for the induction of general anesthesia and facilitation of endotracheal intubation. As defined in clinical studies by The University of Texas Health Science Center, Houston, the protocol involves the sequential intravenous administration of lidocaine (1 mg/kg), an opioid such as fentanyl (1-2 mcg/kg), a sedative-hypnotic agent like propofol (1-2 mg/kg), and a non-depolarizing neuromuscular blocking agent, specifically rocuronium (0.6 mg/kg). This combination is designed to provide analgesia, loss of consciousness, and muscle relaxation to ensure optimal conditions for tracheal intubation while maintaining hemodynamic stability. The regimen serves as a control arm in trials evaluating alternative induction techniques like Modified Time Principle Induction (MTPI).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Classic Induction.